Identification | |||||
---|---|---|---|---|---|
Name | Interferon beta-1b | ||||
Accession Number | DB00068 (BIOD00078, BTD00078) | ||||
Type | biotech | ||||
Description | Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD | ||||
Structure |
|
||||
Categories (*) | |||||
Molecular Weight | 20011.0000 | ||||
Groups | approved | ||||
Monoisotopic Weight | Not Available | ||||
Pharmacology | |||||
Indication | Interferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks. | ||||
Mechanism of action | Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha. | ||||
Absorption | Not Available | ||||
Protein binding | Not Available | ||||
Biotransformation | Not Available | ||||
Route of elimination | Not Available | ||||
Toxicity | Not Available | ||||
Affected organisms |
|
||||
Interactions | |||||
Drug Interactions |
|
||||
Food Interactions | Not Available |
Interferon-alpha/beta receptor alpha chain | |
---|---|
Name | Interferon-alpha/beta receptor alpha chain |
Gene Name | IFNAR1 |
Pharmacological action | yes |
Actions | agonist |
References |
|
DTHybrid score | 1.8511 |
Interferon-alpha/beta receptor beta chain | |
Name | Interferon-alpha/beta receptor beta chain |
Gene Name | IFNAR2 |
Pharmacological action | yes |
Actions | agonist |
References |
|
DTHybrid score | 1.8511 |
Id | Partner name | Gene Name | Score |
---|